From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

from BioMarin Pharmaceutical Inc. Spruce went public during the biotech IPO boom of 2020-21 at $15. Spruce is racing financial and regulatory time in taking over development of TA-ERT from now ...

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Learn more about whether Amarin Corporation plc or Catalyst Pharmaceuticals, Inc. is a better investment based on AAII's A+ ...

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business.

Sequentify is offering research grants to accelerate high-impact genomic studies through its uniquely fast, easy-to-use, and scalable targeted library preparation technology. Designed to enable the ...